The U.S. Food and Drug Administration granted accelerated approval to Otsuka Pharmaceutical’s sibeprenlimab (Voyxact) for adults with primary immunoglobulin A nephropathy (IgAN). The approval is based on interim results from the phase III Visionary trial showing a substantial reduction in proteinuria versus placebo at nine months and supportive 12‑month interim data presented at Kidney Week. Otsuka acquired the antibody via a prior buyout of Visterra; Voyxact is the first approved therapy that targets APRIL, a cytokine implicated in IgAN pathogenesis. Company statements and the FDA filing highlight consistent effects across prespecified subgroups and a safety profile comparable to placebo in the reported safety set. Regulators will continue to follow the ongoing 24‑month data for changes in kidney function (eGFR). Clinicians and payors will watch longer-term renal outcomes and post‑approval data that could determine uptake and positioning relative to other emerging agents targeting B‑cell pathways.